Table 1.

Patient characteristics at baseline (ISS stage and FISH studies) and near day 100 post-ASCT (serum M spike, sFLC ratio, CR status, maintenance therapy)

	Entire cohort, n = 229	Day 100 PET+, n = 149	Day 100 PET−, n = 80	P
Serum M spike at day 100, median (range), g/dL	0.2 (0-2.7)	0 (0-2.7)	0.4 (0-2.6)
sFLC ratio at day 100, median (range)	1.4 (0-1444)	1.36 (0-1445)	1.66 (0.02-497)
ISS stage III*	43/156 (28)	28/156 (18)	15/156 (9.6)	.81
High-risk FISH*	42/170 (24.7)	29/170 (17)	13/170 (7.6)	.5
CR at day 100*	51/221 (23)	30/221 (13.6)	21/221 (9.5)	.37
Maintenance therapy*	62/220 (28)	37/220 (17)	25/220 (11)	.39

FISH, fluorescence in situ hybridization; ISS, International Staging System; sFLC, serum free light chain.

^*Reported as number of patients among the entire cohort with available prognostic data per variable (percentage).